Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (545)	5/15/1999 2:11:00 PM
From: scaram(o)uche	Respond to of 4474

Mike: I was one of the first to study graft-versus-leukemia..... for those with curiosity and access to a good med library, Fed. Proc. 35, 312 (1976), "Inhibition of Leukemia Progression in Rats by the Graft Versus Host Reaction". That's an abstract. Tons of good and conclusive data, but I never wrote it up. That's one reason why I'm an investor rather than an academic. In a world of "publish or perish", I was always more interested in asking questions than in writing. There are many labels that can be placed on such behavior, but the scientists here at SI will certainly include "dumb" among them. I just punt and lean back on the formal diagnoses from the clinical psychologists. In any event, I've followed the observations in GvL for over 20 years. If you're interested in the subject, I'd suggest looking at BTRN and the latest results from Megan Sykes. I agree with you.... a means to control the effector cell is needed. But.... for ARIA, the individual components of the process need to be tested before the process itself can be used. That long testing period is the reason that I bailed when the company couldn't deliver as [nearly] promised for osteoporosis. A wreck in slow motion. Cheers! Rick